Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

522 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Hybridizing mechanistic mathematical modeling with deep learning methods to predict individual cancer patient survival after immune checkpoint inhibitor therapy.
Butner JD, Dogra P, Chung C, Koay EJ, Welsh JW, Hong DS, Cristini V, Wang Z. Butner JD, et al. Among authors: hong ds. Res Sq [Preprint]. 2024 Mar 29:rs.3.rs-4151883. doi: 10.21203/rs.3.rs-4151883/v1. Res Sq. 2024. Update in: NPJ Syst Biol Appl. 2024 Aug 14;10(1):88. doi: 10.1038/s41540-024-00415-8 PMID: 38586046 Free PMC article. Updated. Preprint.
Phase I study of BMS-986299, an NLRP3 agonist, as monotherapy and in combination with nivolumab and ipilimumab in patients with advanced solid tumors.
Nelson BE, O'Brien S, Sheth RA, Hong DS, Naing A, Zhang X, Xu A, Hamuro L, Suryawanshi R, McKinley D, Novosiadly RD, Piha-Paul SA. Nelson BE, et al. Among authors: hong ds. J Immunother Cancer. 2025 Jan 16;13(1):e010013. doi: 10.1136/jitc-2024-010013. J Immunother Cancer. 2025. PMID: 39824531 Free PMC article. Clinical Trial.
Impact of co-mutations and transcriptional signatures in non-small cell lung cancer patients treated with adagrasib in the KRYSTAL-1 trial.
Negrao MV, Paula AG, Molkentine D, Hover L, Nilsson M, Vokes N, Engstrom L, Calinisan A, Briere DM, Waters L, Hallin J, Diao L, Altan M, Blumenschein GR, Skoulidis F, Wang J, Kopetz SE, Hong DS, Gibbons DL, Olson P, Christensen JG, Heymach JV. Negrao MV, et al. Among authors: hong ds. Clin Cancer Res. 2025 Jan 13. doi: 10.1158/1078-0432.CCR-24-2310. Online ahead of print. Clin Cancer Res. 2025. PMID: 39804166
Obesity and Outcomes in Adoptive Cellular Therapy in Solid Tumors.
Tao DL, Nardo M, Leung CH, Lin HY, Kang L, Le H, Dumbrava EE, Hong DS. Tao DL, et al. Among authors: hong ds. JAMA Netw Open. 2024 Nov 4;7(11):e2447617. doi: 10.1001/jamanetworkopen.2024.47617. JAMA Netw Open. 2024. PMID: 39585697 Free PMC article.
Best Practice Guidelines for Use of Reference Points in Radiation Oncology Information Systems to Aggregate Longitudinal Dosimetric Data.
Witztum A, Jourani Y, Hirata EY, McNutt T, Tadic T, Brock KK, Hong DS, Howard ME, Krauze AV, Balter PA, Stockham AL, Covington EL, Xiao Y, Popple R, Mayo CS. Witztum A, et al. Among authors: hong ds. Pract Radiat Oncol. 2024 Nov 13:S1879-8500(24)00300-X. doi: 10.1016/j.prro.2024.09.016. Online ahead of print. Pract Radiat Oncol. 2024. PMID: 39542396
A Phase Ib Study of Selinexor in Combination with Pembrolizumab in Patients with Metastatic Melanoma.
Gouda MA, Stephen B, Tian Y, Alshawa A, Onwugaje DOC, Albittar A, Yang Y, Zarifa A, Yilmaz B, Gurses S, Sprenger A, Derbala MH, Brink A, How JA, Moyers J, Piha-Paul SA, Hong DS, Meric-Bernstam F, Patel SP, Oliva IG. Gouda MA, et al. Among authors: hong ds. J Immunother Precis Oncol. 2024 Nov 1;7(4):247-254. doi: 10.36401/JIPO-24-3. eCollection 2024 Nov. J Immunother Precis Oncol. 2024. PMID: 39524469 Free PMC article.
522 results